To test, or not to test: that is the question for the future of lipoprotein(a)

References

• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec;31(23):2844–2853. PubMed PMID: 20965889; PubMed Central PMCID: PMC3295201.
   PubMed Web of Science ®Google Scholar
• Crawford DC, Peng Z, Cheng JF, et al. LPA and PLG sequence variation and kringle IV-2 copy number in two populations. Hum Hered. 2008;66(4):199–209. PubMed PMID: ISI:000258984500001; English.
   PubMed Web of Science ®Google Scholar
• Berg K. A new serum type system in man–the Lp system. Acta Pathol Microbiol Immunol Scand. 1963;59: 369–382. PubMed PMID: 14064818.
   Google Scholar
• Schmidt K, Noureen A, Kronenberg F, et al. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016 Aug;57(8):1339–1359. PubMed PMID: 27074913; PubMed Central PMCID: PMC4959873.
   PubMed Web of Science ®Google Scholar
• Zekavat SM, Ruotsalainen S, Handsaker RE, et al. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun. 2018 Jul 4;9(1):2606. PubMed PMID: 29973585; PubMed Central PMCID: PMCPMC6031652.
   PubMedGoogle Scholar
• Srinivasan SR, Dahlen GH, Jarpa RA, et al. Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation. 1991 Jul;84(1):160–167. PubMed PMID: 1829398.
   PubMed Web of Science ®Google Scholar
• Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet. 2000 Jul 22;356(9226):279–284. PubMed PMID: 11071182.
   PubMed Web of Science ®Google Scholar
• Low PS, Heng CK, Saha N, et al. Racial variation of cord plasma lipoprotein(a) levels in relation to coronary risk level: a study in three ethnic groups in Singapore. Pediatr Res. 1996 Nov;40(5):718–722. PubMed PMID: 8910937.
   PubMed Web of Science ®Google Scholar
• Anand SS, Enas EA, Pogue J, et al. Elevated lipoprotein(a) levels in South Asians in North America. Metabolism. 1998 Feb;47(2):182–184. PubMed PMID: 9472967.
   PubMed Web of Science ®Google Scholar
• Ellis KL, Boffa MB, Sahebkar A, et al. The renaissance of lipoprotein(a): brave new world for preventive cardiology? Prog Lipid Res. 2017 Sep 06;68:57–82. PubMed PMID: 28888913.
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality [meta-analysis research support, Non-U.S. Gov’t review]. JAMA. 2009 Jul 22;302(4):412–423. PubMed PMID: 19622820; eng.
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 2001 Feb;37(2):434–439. PubMed PMID: 11216959.
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 04;104(10):1108–1113. PubMed PMID: 11535564.
   PubMed Web of Science ®Google Scholar
• Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002 Aug;163(2):377–384. PubMed PMID: 12052486.
   PubMed Web of Science ®Google Scholar
• Ariyo AA, Thach C, Tracy R, et al. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003 Nov 27;349(22):2108–2115. PubMed PMID: 14645638.
   PubMed Web of Science ®Google Scholar
• Rifai N, Ma J, Sacks FM, et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians’ health study. Clin Chem. 2004 Aug;50(8):1364–1371. PubMed PMID: 15155542.
   PubMed Web of Science ®Google Scholar
• Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006 Sep 20;296(11):1363–1370. PubMed PMID: 16985228.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008 Jan 15;117(2):176–184. PubMed PMID: 18086931.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2013 Nov;1(3):220–227. PubMed PMID: 24622370.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease [Multicenter StudyResearch Support, Non-U.S. Gov’t]. N Engl J Med. 2009 Dec 24;361(26):2518–2528. PubMed PMID: 20032323; eng.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014 Feb 11;63(5):470–477. PubMed PMID: 24161338.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014 Jun;7(3):304–310. PubMed PMID: 24704946.
   PubMed Web of Science ®Google Scholar
• Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017 Apr 10;5:524–533. PubMed PMID: 28408323.
   PubMed Web of Science ®Google Scholar
• Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. PubMed PMID: 2542796.
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Gavish D, Breslow JL, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. PubMed PMID: 2524666.
   PubMed Web of Science ®Google Scholar
• Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003 Jun 27;278(26):23260–23269. PubMed PMID: 12697748.
   PubMed Web of Science ®Google Scholar
• Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1393–1399. PubMed PMID: 9743227.
   PubMed Web of Science ®Google Scholar
• Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001 Nov 15;98(10):2980–2987. PubMed PMID: 11698280.
   PubMed Web of Science ®Google Scholar
• Undas A, Stepien E, Tracz W, et al. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006 May;4(5):973–975. PubMed PMID: 16689745.
   PubMed Web of Science ®Google Scholar
• Undas A, Plicner D, Stepien E, et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost. 2007 Sep;5(9):1988–1990. PubMed PMID: 17723142.
   PubMed Web of Science ®Google Scholar
• Rowland CM, Pullinger CR, Luke MM, et al. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties. Thromb Res. 2014 May;133(5):863–867. PubMed PMID: 24502962.
   PubMed Web of Science ®Google Scholar
• Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC, et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem. 2004 Feb 20;279(8):6526–6533. PubMed PMID: 14660654.
   PubMed Web of Science ®Google Scholar
• Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV(10ʹ), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem. 2008 Nov 7;283(45):30503–30512. PubMed PMID: 18776185; PubMed Central PMCID: PMC2662143.
   PubMed Web of Science ®Google Scholar
• Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010 Nov 3;12(5):467–482. PubMed PMID: 21035758; PubMed Central PMCID: PMC2991104.
   PubMed Web of Science ®Google Scholar
• Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003 Dec 26;278(52):52841–52847. PubMed PMID: 14557258.
   PubMed Web of Science ®Google Scholar
• Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015 Dec;56(12):2273–2285. PubMed PMID: 26474593; PubMed Central PMCID: PMCPMC4655984.
   PubMed Web of Science ®Google Scholar
• van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016 Aug 23;134(8):611–624. PubMed PMID: 27496857; PubMed Central PMCID: PMCPMC4995139.
   PubMed Web of Science ®Google Scholar
• Rouy D, Koschinsky ML, Fleury V, et al. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry. 1992 Jul 14;31(27):6333–6339. PubMed PMID: 1627572.
   PubMed Web of Science ®Google Scholar
• Biemond BJ, Friederich PW, Koschinsky ML, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation. 1997 Sep 2;96(5):1612–1615. PubMed PMID: 9315555.
   PubMed Web of Science ®Google Scholar
• van Montfoort ML, Kuijpers MJ, Knaup VL, et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1668–1673. PubMed PMID: 24947525.
   PubMed Web of Science ®Google Scholar
• Hughes SD, Lou XJ, Ighani S, et al. Lipoprotein(a) vascular accumulation in mice. in vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest. 1997 Sep 15;100(6):1493–1500. PubMed PMID: 9294116; PubMed Central PMCID: PMCPMC508329.
   PubMed Web of Science ®Google Scholar
• Boonmark NW, Lou XJ, Yang ZJ, et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest. 1997 Aug 1;100(3):558–564. PubMed PMID: 9239402; PubMed Central PMCID: PMCPMC508222.
   PubMed Web of Science ®Google Scholar
• Sun H, Unoki H, Wang X, et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem. 2002 Dec 06;277(49):47486–47492. PubMed PMID: 12196525.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018 Jan 16;71(2):177–192. PubMed PMID: 29325642; PubMed Central PMCID: PMC5868960.
   PubMed Web of Science ®Google Scholar
• Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014 Sep 2;64(9):851–860. PubMed PMID: 25169167.
   PubMed Web of Science ®Google Scholar
• Verbeek R, Sandhu MS, Hovingh GK, et al. Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms. J Am Coll Cardiol. 2017 Mar 21;69(11):1513–1515. PubMed PMID: 28302296.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013 Mar 19;61(11):1146–1156. PubMed PMID: 23375930.
   PubMed Web of Science ®Google Scholar
• Fogacci F, Cicero AFG, D’Addato S, et al. Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. Eur J Intern Med. 2017;37:49–55.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012 Jun 20;307(23):2499–2506. PubMed PMID: 22797450; PubMed Central PMCID: PMC4211641.
   PubMed Web of Science ®Google Scholar
• Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017 Apr 24 PubMed PMID: 28449027. DOI:10.1093/eurheartj/ehx166.
   PubMed Web of Science ®Google Scholar
• Boffa MB, Stranges S, Klar N, et al. Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal. J Clin Lipidol. 2018 Sep 11;12:1358–1366. PubMed PMID: 30316749.
   PubMed Web of Science ®Google Scholar
• Berg K, Dahlen G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet. 1997 Nov;52(5):254–261. PubMed PMID: 9520115.
   PubMed Web of Science ®Google Scholar
• Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2902–2908. PubMed PMID: 24092750.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014;9(12):e114519. PubMed PMID: 25531109; PubMed Central PMCID: PMCPMC4273994.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000 Apr 12;283(14):1845–1852. PubMed PMID: 10770146.
   PubMed Web of Science ®Google Scholar
• Albers JJ, Slee A, O’Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013 Oct 22;62(17):1575–1579. PubMed PMID: 23973688; PubMed Central PMCID: PMC3800510.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014 Feb 18;63(6):520–527. PubMed PMID: 24161323; PubMed Central PMCID: PMCPMC3945105.
   PubMed Web of Science ®Google Scholar
• Zewinger S, Kleber ME, Tragante V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017. DOI:10.1016/S2213-8587(17)30096-7.
   Web of Science ®Google Scholar
• Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol. 2018 Feb 1;3(2):164–168. PubMed PMID: 29071331; PubMed Central PMCID: PMCPMC5838593.
   PubMed Web of Science ®Google Scholar
• Lázaro P, Pérez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260–271.
   PubMed Web of Science ®Google Scholar
• Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014 Jul-Aug;8(4):390–400. PubMed PMID: 25110220.
   PubMed Web of Science ®Google Scholar
• Ellis KL, Pang J, Chieng D, et al. Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: between scylla and charybdis. Clin Cardiol. 2018 Mar;41(3):378–384. PubMed PMID: 29480541.
   PubMed Web of Science ®Google Scholar
• Weiss MC, Berger JS, Gianos E, et al. Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J Clin Lipidol. 2017 Jul 22;11:1177–1180. PubMed PMID: 28801030.
   Web of Science ®Google Scholar
• Langsted A, Kamstrup PR, Benn M, et al. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016 Jul;4(7):577–587. PubMed PMID: 27185354.
   PubMed Web of Science ®Google Scholar
• Chan DC, Pang J, Hooper AJ, et al. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol. 2015 Aug 21;201:633–638. PubMed PMID: 26340131.
   PubMed Web of Science ®Google Scholar
• Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014 May 20;63(19):1982–1989. PubMed PMID: 24632281.
   PubMed Web of Science ®Google Scholar
• Alonso R, Mata P, Muniz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis. 2016 Nov;254:249–253. PubMed PMID: 27594539.
   PubMed Web of Science ®Google Scholar
• Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017 May 30;135(22):2133–2144. PubMed PMID: 28275165.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9(2):129–169.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016. DOI:10.1016/j.atherosclerosis.2016.08.018.
   Web of Science ®Google Scholar
• Anderson TJ, Gregoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016 Nov;32(11):1263–1282. PubMed PMID: 27712954.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Julius U, Watts GF, et al. Towards an international consensus–integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol. 2017;11:858–871.e3.
   Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018. doi: 10.1016/j.jacc.2018.11.003.
   Google Scholar
• Brown WV, Ballantyne CM, Jones PH, et al. Management of Lp(a). J Clin Lipidol. 2010 Jul-Aug;4(4):240–247. PubMed PMID: 21122656.
   PubMed Web of Science ®Google Scholar
• McConnell JP, Guadagno PA, Dayspring TD, et al. Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol. 2014 Nov-Dec;8(6):550–553. PubMed PMID: 25499936.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000 Dec;46(12):1956–1967. PubMed PMID: ISI:000165722200011; English.
   PubMed Web of Science ®Google Scholar
• Lassman ME, McLaughlin TM, Zhou H, et al. Simultaneous quantitation and size characterization of apolipoprotein (a) by ultra‐performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2014;28(10):1101–1106.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016 Apr;57(4):526–537. PubMed PMID: 26637278; PubMed Central PMCID: PMCPMC4808779
   PubMed Web of Science ®Google Scholar
• Perrot N, Verbeek R, Sandhu M, et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study. Atherosclerosis. 2017 Jan;256:47–52. PubMed PMID: 27998826; PubMed Central PMCID: PMC5321848.
   PubMed Web of Science ®Google Scholar
• Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):141–158. PubMed PMID: 24363242.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017 Mar 17;376:1430–1440. PubMed PMID: 28306389; eng.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012 Jun 19;59(25):2344–2353. PubMed PMID: 22463922.
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012 Nov 15;367(20):1891–1900. PubMed PMID: 23113833.
   PubMed Web of Science ®Google Scholar
• Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 1;35(33):2249–2259. PubMed PMID: 24598985.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014 Sep 1;114(5):711–715. PubMed PMID: 25060413.
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013 Aug 27;128(9):962–969. PubMed PMID: 23884353.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 8;63(13):1278–1288. PubMed PMID: 24509273.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489–1499. PubMed PMID: 25773378.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809–1819. PubMed PMID: 24678979.
   PubMed Web of Science ®Google Scholar
• Bambauer R, Bambauer C, Lehmann B, et al. LDL-apheresis: technical and clinical aspects. ScientificWorldJournal. 2012;2012:314283. PubMed PMID: 22654591; PubMed Central PMCID: PMC3361163.
   PubMedGoogle Scholar
• Schamberger BM, Geiss HC, Ritter MM, et al. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res. 2000 May;41(5):727–733. PubMed PMID: 10787433.
   PubMed Web of Science ®Google Scholar
• University of Oxford MSaDC. REVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification. Bethesda, MD: National Library of Medicine (US). 2000. ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT01252953NLM Identifier: NCT01252953.
   Google Scholar
• Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia [10.1038/ncpcardio1250]. Nat Clin Pract Cardiovasc Med. 2008;5(8):497–505. 08//print;
   PubMedGoogle Scholar
• Cuchel M, Meagher EA, Du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40–46.
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal FJ. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014 Dec;43(4):1007–1033. PubMed PMID: 25432394.
   PubMed Web of Science ®Google Scholar
• Howard BV, Rossouw JE. Estrogens and cardiovascular disease risk revisited: the women’s health initiative. Curr Opin Lipidol. 2013 Dec;24(6):493–499. PubMed PMID: 24184944; PubMed Central PMCID: PMC4219554.
   PubMed Web of Science ®Google Scholar
• Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol. 2014 Dec;25(6):452–460. PubMed PMID: 25318824.
   PubMed Web of Science ®Google Scholar
• Shoemaker TJ, Kono T, Mariash CN, et al. Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? Endocr Pract. 2012 Nov-Dec;18(6):954–964. PubMed PMID: 22784847; PubMed Central PMCID: PMC3745011.
   PubMed Web of Science ®Google Scholar
• Pramfalk C, Pedrelli M, Parini P. Role of thyroid receptor beta in lipid metabolism. Biochim Biophys Acta. 2011 Aug;1812(8):929–937. PubMed PMID: 21194564.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015 Apr;74(4):694–702. PubMed PMID: 24368514; PubMed Central PMCID: PMC4392313.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Viney N, Crooke RM, et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–351.
   PubMed Web of Science ®Google Scholar
• Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. PubMed PMID: 27665230 Sep 21 2016. Doi:10.1016/S0140-6736(16)31009-1.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Safety and efficacy of AKCEA-APO(a)-LRX to lower lipoprotein(a) levels in patients with established cardiovascular disease: A phase 2 dose-ranging trial. AHA Scientific Sessions 2018, Chicago, November 10–12 2018.
   Google Scholar
• Available from: http://www.amgen.com/media/news-releases/2016/09/amgen-and-arrowhead-pharmaceuticals-announce-two-cardiovascular-collaborations/.
   Google Scholar
• Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018 Jul 1;3(7):619–627. PubMed PMID: 29926099.
   PubMed Web of Science ®Google Scholar
• Roeseler E, Julius U, Heigl F, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2019–2027. PubMed PMID: 27417585.
   PubMed Web of Science ®Google Scholar
• Klingel R, Heibges A, Fassbender C, et al. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):38–43. PubMed PMID: 28185214; PubMed Central PMCID: PMC5352778.
   PubMedGoogle Scholar
• Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–239.
   PubMedGoogle Scholar
• Ezhov M, Safarova M, Afanasieva O, et al. Specific Lipoprotein (a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein (a) levels. Atherosclerosis Suppl. 2015;18:163–169.
   PubMed Web of Science ®Google Scholar
• Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein (a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Suppl. 2013;14(1):93–99.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein (a), PCSK9 Inhibition and cardiovascular risk: insights from the Fourier trial. Circulation. 2019;139(12):1483-1492.
   Google Scholar
• Bittner V, Szarek M, Aylward PE et al. The ODYSSEY OUTCOMES trial: lp(a) and cardiovacsular outcomes. 18th International Symposium on Atherosclerosis, June 12th 2018, Toronto, Canada 2018
   Google Scholar
• Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018 Oct 13;392(10155):1311–1320. PubMed PMID: 30293769.
   PubMed Web of Science ®Google Scholar
• Stroes E. A randomized double-blind placebo-controlled study characterizing the effects of proprotein convertase subtilisin/kexin type 9 inhibition on arterial wall inflammation in patients with elevated lipoprotein(a) (ANITSCHKOW). AHA Scientific Sessions 2018, Chicago,November 10–12 2018.
   Google Scholar
• Ellis KL, Pang J, Chan DC, et al. Familial combined hyperlipidemia and hyperlipoprotein (a) as phenotypic mimics of familial hypercholesterolemia: frequencies, associations and predictions. J Clin Lipidol. 2016;10(6):1329–1337 e3.
   PubMed Web of Science ®Google Scholar